Stephane van Rooijen
Amministratore Delegato presso Dynacure SA
Posizioni attive di Stephane van Rooijen
Società | Posizione | Inizio | Fine |
---|---|---|---|
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Direttore/Membro del Consiglio | 01/01/2016 | - |
Amministratore Delegato | 01/01/2016 | - | |
Viropharma Ltd.
Viropharma Ltd. Pharmaceuticals: MajorHealth Technology Viropharma Ltd. manufactures pharmaceutical products. The company was founded on May 14, 2007 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/01/2014 | - |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | 01/01/2023 | - | |
Presidente | - | - |
Storia della carriera di Stephane van Rooijen
Precedenti posizioni note di Stephane van Rooijen
Società | Posizione | Inizio | Fine |
---|---|---|---|
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Amministratore Delegato | 01/01/2014 | 01/01/2016 |
Formazione di Stephane van Rooijen
Katholieke Universiteit Leuven | Doctorate Degree |
Erasmus University Rotterdam | Masters Business Admin |
Statistiche
Distribuzione geografica
Belgio | 4 |
Francia | 2 |
Paesi Bassi | 2 |
Posizioni
Chief Executive Officer | 3 |
Director/Board Member | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
Viropharma Ltd.
Viropharma Ltd. Pharmaceuticals: MajorHealth Technology Viropharma Ltd. manufactures pharmaceutical products. The company was founded on May 14, 2007 and is headquartered in London, the United Kingdom. | Health Technology |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Commercial Services |
- Borsa valori
- Insiders
- Stephane van Rooijen
- Esperienza